Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA163972
Max Phase: Preclinical
Molecular Formula: C20H18O4
Molecular Weight: 322.36
Molecule Type: Small molecule
Associated Items:
ID: ALA163972
Max Phase: Preclinical
Molecular Formula: C20H18O4
Molecular Weight: 322.36
Molecule Type: Small molecule
Associated Items:
Synonyms (1): 6-Prenylchrysin
Synonyms from Alternative Forms(1):
Canonical SMILES: CC(C)=CCc1c(O)cc2oc(-c3ccccc3)cc(=O)c2c1O
Standard InChI: InChI=1S/C20H18O4/c1-12(2)8-9-14-15(21)10-18-19(20(14)23)16(22)11-17(24-18)13-6-4-3-5-7-13/h3-8,10-11,21,23H,9H2,1-2H3
Standard InChI Key: SIXNWJHCSFYZBN-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 322.36 | Molecular Weight (Monoisotopic): 322.1205 | AlogP: 4.38 | #Rotatable Bonds: 3 |
Polar Surface Area: 70.67 | Molecular Species: ACID | HBA: 4 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 6.39 | CX Basic pKa: | CX LogP: 4.74 | CX LogD: 3.63 |
Aromatic Rings: 3 | Heavy Atoms: 24 | QED Weighted: 0.70 | Np Likeness Score: 1.72 |
1. Comte G, Daskiewicz JB, Bayet C, Conseil G, Viornery-Vanier A, Dumontet C, Di Pietro A, Barron D.. (2001) C-Isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance., 44 (5): [PMID:11262086] [10.1021/jm991128y] |
2. Daskiewicz JB, Depeint F, Viornery L, Bayet C, Comte-Sarrazin G, Comte G, Gee JM, Johnson IT, Ndjoko K, Hostettmann K, Barron D.. (2005) Effects of flavonoids on cell proliferation and caspase activation in a human colonic cell line HT29: an SAR study., 48 (8): [PMID:15828817] [10.1021/jm040770b] |
3. Valdameri G, Genoux-Bastide E, Peres B, Gauthier C, Guitton J, Terreux R, Winnischofer SM, Rocha ME, Boumendjel A, Di Pietro A.. (2012) Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein., 55 (2): [PMID:22165858] [10.1021/jm201404w] |
4. Zattoni IF, Delabio LC, Dutra JP, Kita DH, Scheiffer G, Hembecker M, Pereira GDS, Moure VR, Valdameri G.. (2022) Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators., 237 [PMID:35483322] [10.1016/j.ejmech.2022.114346] |
5. Moinul M, Amin SA, Jha T, Gayen S.. (2022) Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development., 241 [PMID:35944339] [10.1016/j.ejmech.2022.114628] |
Source(1):